Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice

British Journal of Pharmacology

Volumn 169, Issue 7, 2013, Pages 1587-1599

  Trapeaux, J ^a   Busseuil, D ^a   Shi, Y ^a   Nobari, S ^b   Shustik, D ^a   Mecteau, M ^a   El Hamamsy, I ^a   Lebel, M ^c   Mongrain, R ^a,b,d   Rheaume E ^a,d   Tardif, J C ^a,d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

aortic valve stenosis; collagen; fibrosis; HDL; mouse model

Indexed keywords

APOLIPOPROTEIN A1; COLLAGEN TYPE 1; COLLAGEN TYPE 3; PLACEBO; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; AORTA SINUS; AORTA VALVE; AORTA VALVE STENOSIS; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; GENE; GENE DELETION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WERNER PROGERIA GENE;

AORTIC VALVE STENOSIS; COLLAGEN; FIBROSIS; HDL; MOUSE MODEL;

ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; APOLIPOPROTEIN A-I; BIOMIMETIC MATERIALS; COLLAGEN; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; GENE EXPRESSION REGULATION; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; PEPTIDES;

EID: 84880270197     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12236     Document Type: Article

References (48)

1. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, et al. (2007). Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115: 377-386.
2. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al. (2009). Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 119: 1785-1794.
3. Busseuil D, Shi Y, Mecteau M, Brand G, Kernaleguen AE, Thorin E, et al. (2008). Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol 154: 765-773.
4. Capell BC, Collins FS, Nabel EG, (2007). Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res 101: 13-26.
5. Carabello BA, Paulus WJ, (2009). Aortic stenosis. Lancet 373: 956-966.
6. Drolet MC, Arsenault M, Couet J, (2003). Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 41: 1211-1217.
7. Drolet MC, Roussel E, Deshaies Y, Couet J, Arsenault M, (2006). A high fat/high carbohydrate diet induces aortic valve disease in C57Bl/6J mice. J Am Coll Cardiol 47: 850-855.
8. Fokin AA, Robicsek F, Cook JW, Thubrikar MJ, Schaper J, (2004). Morphological changes of the aortic valve leaflets in non-compliant aortic roots: in-vivo experiments. J Heart Valve Dis 13: 444-451.
9. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, et al. (2005). Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26: 1333-1341.
10. Freeman RV, Otto CM, (2005). Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111: 3316-3326.
11. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, et al. (2002). Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91: 852-859.
12. Grimard BH, Larson JM, (2008). Aortic stenosis: diagnosis and treatment. Am Fam Physician 78: 717-724.
13. Grubitzsch H, Beholz S, Wollert HG, Eckel L, (2000). Severe heart valve calcification in a young patient with Werner syndrome. Cardiovasc Pathol 9: 53-54.
14. Guerraty M, Mohler IIIER, (2007). Models of aortic valve calcification. J Invest Med 55: 278-283.
15. Helske S, Kupari M, Lindstedt KA, Kovanen PT, (2007). Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 18: 483-491.
16. Hinton RB, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, et al. (2006). Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 98: 1431-1438.
17. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, et al. (2010). Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J 31: 1975-1984.
18. Johnson JL, George SJ, Newby AC, Jackson CL, (2005). Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 102: 15575-15580.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
20. Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, et al. (2010). Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 182: 633-642.
21. Lebel M, Leder P, (1998). A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc Natl Acad Sci U S A 95: 13097-13102.
22. van der Linde D, Yap SC, van Dijk AP, Budts W, Pieper PG, van der Burgh PH, et al. (2011). Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). Am J Cardiol 108: 265-271.
23. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. (2000). Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31: 40-47.
24. Lommi JI, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Kupari M, Helske S, (2011). High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis 219: 538-544.
25. Makous N, Friedman S, Yakovac W, Maris EP, (1962). Cardiovascular manifestations in progeria. Report of clinical and pathologic findings in a patient with severe arteriosclerotic heart disease and aortic stenosis. Am Heart J 64: 334-346.
26. Marijianowski MM, Teeling P, Mann J, Becker AE, (1995). Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 25: 1263-1272.
27. Massip L, Garand C, Turaga RV, Deschênes F, Thorin E, Lebel M, (2006). Increased insulin, triglycerides, reactive oxygen species, and cardiac fibrosis in mice with a mutation in the helicase domain of the Werner syndrome gene homologue. Exp Gerontol 41: 157-168.
28. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. Meyers CD, Kashyap ML, (2005). Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 20: 307-312.
30. Miller JD, Weiss RM, Serrano KM, Castaneda LE, Brooks RM, Zimmerman K, et al. (2010). Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease. Arterioscler Thromb Vasc Biol 30: 2482-2486.
31. Miller JD, Weiss RM, Heistad DD, (2011). Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 108: 1392-1412.
32. Nemes A, Forster T, Csanady M, (2007). Reduction of coronary flow reserve in patients with increased aortic stiffness. Can J Physiol Pharmacol 85: 818-822.
33. Nichol JW, Khan AR, Birbach M, Gaynor JW, Gooch KJ, (2009). Hemodynamics and axial strain additively increase matrix remodeling and MMP-9, but not MMP-2, expression in arteries engineered by directed remodeling. Tissue Eng Part A 15: 1281-1290.
34. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-2300.
35. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. (2006). Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556-1565.
36. Nobari S, Mongrain R, Campbell I, Leask R, Cartier R, (2009a). Assessment of pathological conditions using a 3D model of the aortic valve. 6th Interdisciplinary Graduate Student Research Symposium; 2009 March; McGill University.
37. Nobari S, Mongrain R, Campbell I, Leask R, Cartier R, (2009b). Derivation of surrogate variables to assess pathological conditions using a 3D model of the aortic valve. ASME Summer Bio-engineering Conference 2009. PT A-B: 967-968.
38. Nobari S, Mongrain R, Gaillard E, Leask R, Cartier R, (2012). Therapeutic vascular compliance change may cause significant variation in coronary perfusion: a numerical study. Comput Math Methods Med 2012: 791686. doi: 10.1155/2012/791686.
39. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, et al. (1999). Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99: 2750-2756.
40. Rajamannan NM, (2009). Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 29: 162-168.
41. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. (2011). Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 124: 1783-1791.
42. Rollé F, Cornu E, Virot P, Chauvreau C, Christidès C, Laskar M, (1997). Calcified aortic valvular disease associated with adult progeria. Arch Mal Coeur Vaiss 90: 1663-1665.
43. Salas MJ, Santana O, Escolar E, Lamas GA, (2012). Medical therapy for calcific aortic stenosis. J Cardiovasc Pharmacol Ther 17: 133-138.
44. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, et al. (2010). Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J 31: 2049-2057.
45. Sripathi VC, Kumar RK, Balakrishnan KR, (2004). Further insights into normal aortic valve function: role of a compliant aortic root on leaflet opening and valve orifice area. Ann Thorac Surg 77: 844-851.
46. Tabet F, Rye KA, (2009). High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 116: 87-98.
47. Tanaka K, Sata M, Fukuda D, Suematsu Y, Motomura N, Takamoto S, et al. (2005). Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 46: 134-141.
48. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, et al. (2007). Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675-1682.